Product logins

Find logins to all Clarivate products below.


Glomerulonephritis – Current Treatment – Current Treatment: Physician Insights – Glomerulonephritis (US)

Glomerulonephritis (GN) is a condition involving inflammation of the glomerulus, which plays an important role in the filtration of blood into the kidney. If the glomerulus becomes inflamed and damaged, there can be a decline in kidney function, leading to chronic kidney disease (CKD). While mild GN cases may not require drug intervention, severe cases are managed with therapies like corticosteroids and immunosuppressants. This content delves deep into the dynamics of the GN therapy market, examining the management of GN patients from the perspective of nephrologists. We focus on how GN disorders, such as immunoglobulin A (IgA) nephropathy, focal segmental glomerulosclerosis (FSGS), lupus nephritis (LN), and membranous nephropathy (MN), are being treated in the United States today and the factors behind those treatment decisions.

Questions answered

  • What are U.S. specialists’ attitudes and perceptions regarding the diagnosis and management of patients with IgAN, FSGS, LN, or MN?
  • What percentage of GN patients are prescribed pharmacotherapy?
  • What are the key drug classes that nephrologists use to manage patients with GN?
  • How does treatment differ for patients with IgAN, FSGS, LN, or MN?
  • How do nephrologists adjust pharmacotherapy in response to disease progression?

Content highlights

  • Geography: United States
  • Primary research: survey of 102 U.S. nephrologists
  • Key drugs covered: RAAS inhibitors, corticosteroids, immunosuppressants
  • Key insights provided:
    • Factors influencing disease management and treatment decisions
    • Drivers and constraints of treatment selection
    • Physician-reported treatment practices and brand-level patient shares
    • Rationale for changes in treatment approach
    • Physician insight on persistency and compliance
    • Physician-reported recent / anticipated changes in brand usage or treatment approach

Product description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Related Market Assessment Reports

Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
Report
Membranous Nephropathy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Primary membranous nephropathy (pMN), the most common type of MN, is a rare autoantibody-mediated autoimmune kidney disease. Although it is one of the leading causes of nephrotic syndrome in…
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms – Claims Data Analysis – IBS-Diarrhea (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. The disorder is grouped into three…